검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 177Lu-PNT2002 |
Overview Company | Lantheus Medical Imaging |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Renal Cell Carcinoma |
Overview Indication | Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Secondary endpoints are radiographic and prostate-specific antigen-based progression, acute and late physician-scored toxicity, patient-reported quality of life, ADT-free survival, time to progression, overall survival, locoregional control, and duration of response. |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).. To assess the efficacy of 177 Lu-PNT2002, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in combination with stereotactic body radiotherapy (SBRT) to all sites of metastasis, vs S… |
Clinical Primary efficacy | ORR 32% |
Clinical ORR | 30.1% |
Clinical PFS | 9.5 |
Clinical Result source | ClinicalTrials.gov NCT04647526 |
Clinical Data Tier / Score | A · 10 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 6월 1일 (43일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 177Lu-PNT2002 |
Overview Company | Lantheus Medical Imaging |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Renal Cell Carcinoma |
Overview Indication | Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Secondary endpoints are radiographic and prostate-specific antigen-based progression, acute and late physician-scored toxicity, patient-reported quality of life, ADT-free survival, time to progression, overall survival, locoregional control, and duration of response. |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).. To assess the efficacy of 177 Lu-PNT2002, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in combination with stereotactic body radiotherapy (SBRT) to all sites of metastasis, vs S… |
Clinical Primary efficacy | ORR 32% |
Clinical ORR | 30.1% |
Clinical PFS | 9.5 |
Clinical Result source | ClinicalTrials.gov NCT04647526 |
Clinical Data Tier / Score | A · 10 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 6월 1일 (43일 전 · 갱신 권장) |
추천 비교
추천 비교